Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01826448
Title A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Plexxikon



Pexidartinib + Vemurafenib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Los Angeles California 90024 United States Details
University of Colorado, Denver Aurora Colorado 80012 United States Details
Vanderbilt University Nashville Tennessee 37232 United States Details
Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
Institute Gustave Roussy Paris France Details
University Hospital Essen Essen Germany Details
*Shaded cells indicate that there was no data available from for the field